Molnupiravir – Antiviral RNA Mutagen Therapy

Molnupiravir is a potent oral antiviral agent that is a prodrug of the synthetic nucleoside analogue N4-hydroxycytidine. The drug was developed specifically to inhibit the replication of RNA viruses and has gained widespread use as a first-line therapy to prevent severe outcomes of coronavirus infection. Molnupiravir acts by introducing critical errors into the viral genetic code, rendering its reproduction impossible.

The mechanism of action of molnupiravir is based on the concept of "lethal mutagenesis." Once in the body, the drug is converted into its active triphosphate form, which mimics natural nucleosides (cytidine or uridine). The viral RNA-dependent RNA polymerase mistakenly incorporates this substance during the synthesis of a new viral RNA strand. During subsequent copying, the active metabolite triggers a cascade of random mutations in the viral genome. When the error load reaches a critical threshold, the virus loses its ability to replicate and produce functional proteins, leading to a rapid reduction in viral load and termination of the infectious process. The drug has a broad spectrum of activity and is effective against various variants of the SARS-CoV-2 virus.

The drug is available in capsule form, allowing treatment to begin immediately after diagnosis in an outpatient setting.

Wikipedia page
Molnupiravir

Indications

Molnupiravir is indicated for the treatment of adult patients with a confirmed viral infection:

  • Coronavirus Disease (COVID-19): treatment of mild-to-moderate infection in adults with positive results of direct SARS-CoV-2 viral testing.
  • High-Risk Groups: therapy for patients who have at least one risk factor for developing severe illness (advanced age, obesity, diabetes, or heart disease).
  • Hospitalization Prevention: use of the drug to reduce the risk of hospitalization and mortality when treatment is initiated promptly.
  • Time Constraints: treatment must be started as soon as possible after diagnosis, and no later than 5 days after the onset of symptoms.

Dosage and administration

The dosing regimen for molnupiravir is strictly regulated and requires completion of the full course to prevent the development of resistance.

  • Standard Dose: the recommended dosage is 800 mg (usually four 200 mg capsules) every 12 hours.
  • Course Duration: treatment is administered for 5 full days. Early termination of the course reduces the effectiveness of the therapy.
  • Administration Method: capsules are taken orally, swallowed whole with water, regardless of food intake.
  • Missed Dose: if the delay is less than 10 hours, the dose should be taken immediately. If more than 10 hours have passed, wait for the next scheduled dose.
  • Special Populations: no dose adjustment is required for patients with renal or hepatic impairment, nor for elderly individuals.

Due to its specific mechanism of action on genetic material, the following restrictions apply to the drug:

  • Pregnancy: use is contraindicated; the drug may cause fetal harm due to potential mutagenic effects.
  • Lactation: breastfeeding is not recommended during therapy and for 4 days after the last dose.
  • Pediatric Use: the drug is strictly contraindicated in individuals under 18 years of age as it may affect bone and cartilage growth.
  • Family Planning: females of childbearing potential and males with partners of childbearing potential should use reliable contraception during and after the course.
  • Hypersensitivity: proven allergy to molnupiravir or any excipient within the capsule.

Molnupiravir is generally well-tolerated, but the following adverse events may be observed:

  • GI Disorders: diarrhea, nausea, and occasionally vomiting are most frequently reported during the first days of treatment.
  • Neurology: dizziness, somnolence, or mild headache, which resolve after the course is completed.
  • Skin Reactions: rash, urticaria, or pruritus (itching) may occur as hypersensitivity reactions.
  • Laboratory Findings: in rare cases, a slight change in liver enzyme levels in the blood plasma may be observed.
  • General Condition: fatigue or general malaise, which can be difficult to distinguish from the symptoms of the underlying viral illness.
  • Mutagenic Potential: a theoretical risk of affecting human cells, which is minimized by strict adherence to the course duration.

Frequently Asked Questions

Molnupiravir is an oral antiviral medication that acts as a nucleoside analogue. Once inside the body, it is converted into a form that the virus mistakenly incorporates when replicating its RNA. Instead of accurate copying, the drug introduces numerous errors (mutations) into the viral genome. Eventually, the number of mutations reaches a critical level ("error catastrophe"), leaving the virus unable to replicate or survive.
Molnupiravir is most effective during the early stages of infection while the virus is actively replicating. Clinical guidelines recommend starting treatment within the first 5 days of symptom onset. If therapy begins later, after the viral load has peaked and inflammation becomes the primary driver of the illness, the drug's effectiveness decreases significantly.
The standard treatment course lasts 5 days. Capsules are taken every 12 hours (morning and evening), with or without food. It is vital to complete the full 5-day course, even if you feel better by the second or third day. This ensures complete suppression of viral replication and helps prevent the development of resistant viral strains.
Animal studies have suggested that molnupiravir could potentially harm fetal development. Women of childbearing age should use reliable contraception during treatment and for 4 days after the final dose. Men who are taking the drug and have a partner of childbearing potential should use effective contraception during therapy and for 3 months following the last dose.
Molnupiravir is generally not authorized for use in patients under the age of 18. This restriction is in place because the drug may affect bone and cartilage growth in children and adolescents. For this age group, alternative antiviral treatments approved for pediatric use should be considered.

List of medicines by active substance

-20%
Molnuvir 200 mg Sacred Leaves
View
Sacred Leaves

Molnuvir

Molnupiravir
200 mg 40 tablets
1438₴ 1798₴
✅ All products loaded (1)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00